The Production Division, which is part of the Vitamed subsidiary, is engaged in the manufacture of prescription drugs, OTC drugs, dermatological preparations, cosmetics, vitamins and nutritional supplements.
The division produces 16 million units per year (on average), approximately 280 different products, in a variety of production departments (sterile production, pills, liquids, creams and powders).
The division’s production provides a pharmaceutical solution to a variety of medical problems, and includes: antibiotics (penicillin and cephalosporin); drops and ointments for the treatment of allergic infections and dryness of the eyes; steroid anti-inflammatories; anxiety and depression; urinary tract pain; fungal infections; anemia and nutritional deficits; heartburn, vomiting and diarrhea; winter illnesses (fever and pain, various type of cough, congestion, ear pain, etc.); muscle and joint pain and skin problems (dryness, disinfection, burns, insect bites, etc.).
The division also possesses an exclusive license to manufacture, market and distribute an innovative preparation, which is anchored by patents in various countries around the world. The preparation is a unique solution designed to protect the skin against substances that are chemically active, including dangerous gases. The preparation is the product of many years of development at the Israel Institute for Biological Research. The preparation is in the process of receiving the indication authorization from the Ministry of Health, and the company is currently in talks with the Ministries of Health and Defense, regarding the processes required in order to begin marketing the product in Israel and/or supply the preparation to emergency institutions.
In the dermo-cosmetics field, the Group owns a leading Israeli brand in the field of baby products (the Baby Pasta line - diaper creams).
In the field of vitamins and nutritional supplements, some of the products manufactured by the division and others are imported and packaged and inspected at the Group’s plants, including the responsibility for registering the product in accordance with the Ministry of Health’s regulations, quality assurance and the labeling.
The division operates three production sites:
- Holon, established in 1994, and which is leased by the company with a long term lease agreement.
- Binyamina, which was purchased in 2003.
- Or Akiva, which was purchased in 2006.
Both these production sites are owned by Vitamed.
In total, the production areas owned by the Company span approximately 15,000 square meters, of which 2,500 square meters can serve for the expansion of the Group’s activity.
The production plants have been issued GMP licenses as required by the Health Ministry.
Over the years, the Group has taken steps to upgrade and expand the division’s production capability. These steps included expanding the production area of the existing departments, acquisition of state-of-the-art equipment, construction according to the strictest specifications of Israel’s Health Ministry, adaptation in order to meet international standards and environmental protection standards. Since that time, the upgrading process has continued, and a number of production departments have been upgraded, leading to an increase in the Group’s production capabilities, enhanced and more efficient production processes. As part of this process, the production departments at the Holon production site have been upgraded, including the sterile production department. Extensive upgrading steps have also been implemented at the galenical production department and the ophthalmology department at the Binyamina production site. Currently, the plants feature a variety of production departments that use various production technologies:
At the Vitamed plant: A sterile site for the production of eye drops, a galencial and disinfection product department, an ointments and dermo-cosmetics department, a department that produces antibiotic capsules and suspensions and a department that produces nutritional supplements.
At the Rekah Plant: A sterile site for the production of ophthalmic ointments, suppository production department, liquids & syrups department, ointments department, pills and capsule department and a nutritional supplement production department.
The division’s production capability is an average of 16 million units per year; and in recent years, the Group has made efforts to expand this capability in order to meet the demand for the Rekah Group’s products on the Israeli market and to expand its activity to additional markets overseas.
Subsequently, the Group is working toward doubling its production capability in the field of antibiotics on the designated production lines, expanding the pill production capability, expanding the ophthalmic product production and assimilating advanced mechanization processes on existing production lines.
The production division possesses a total of 470 production and import licenses for active products that are regularly manufactured and marketed.
The Group has obtained 45 valid export licenses for 11 countries in Africa and the former Soviet Union. Most of the products are prescription drugs. 35 additional products are in the process of registration and renewal.
The production plants have been issued licenses from the Ministry of Health for the manufacture of their products, as well as authorization that they have met the GMP standards, the conditions for receiving this authorization is the meeting the specifications related to the building structure, air-conditioning systems, water, machinery, equipment, documenting production processes and quality control. Meeting the GMP conditions is a condition for receiving licenses for preparations and for maintaining existing licenses.
The Yesodot plant, owned by Rekah, which manufactures nutritional supplements, has been issued GMP, HACCP and ISO licenses.
In October 2012, agreement was signed between Israel and the European Union for reciprocal recognition in the field of Good Manufacturing Practice for pharmaceutical industry. This agreement constitutes the EU’s recognition of the production quality of Israeli pharmaceuticals and the quality of the Medical Supplies. The agreement will enable drugs manufactured in Israel greater access to the European market. Implementation of the agreement will exempt Israeli manufacturers that export to Europe from the need to conduct laboratory tests for each Israeli shipment on European territory. Moreover, results of tests conducted by the Health Ministry’s Control and Standards Institute will be recognized by European Authorities; consequently, the inspections of Israeli pharmaceutical plants conducted by European countries will be made redundant.
The agreement significantly improves the production division’s potential for exporting to Europe and the company is preparing to take advantage of this potential.
The production division’s plants meet accepted production and environmental conditions for modern pharmaceutical plants.
The Industry Division primarily manufactures finished generic drugs (as opposed to raw materials for drugs). In addition, the division develops and registers new generic products each year.
The wide variety of products includes 280 drugs used in various medical fields: Prescription drugs, OTC drugs, dermo-cosmetics, vitamins and nutritional supplements.
The division manufactures antibiotics (penicillin and cephalosporin); drops and ointments for the treatment of allergic infections and dryness of the eyes; disinfectant preparations; dermatological creams, vitamins, baby products line (including the Baby Pasta brand) and nutritional supplements.
In the field of vitamins and nutritional supplements, some of the products are manufactured by the division and others are imported, packaged and inspected at the Group’s plants, including the responsibility for registration in accordance with the Health Ministry’s standards, quality assurance and labeling.
The production division’s products are distributed by the Ophir & Shalpharm marketing division (with the exception of the institutional customers to which it distributes directly).
The Group is in a constant process of development and registration of new products (drugs, OTC products and dermo-cosmetic products) and believes in product innovation as a principal key to long term growth.
On the local market, the Group’s products are purchased by Kupot Holim Healthcare Services, government institutions (Ministry of Defense), institutional parties such as SAREL, hospitals and senior citizens residences, pharmacy retail chains, private pharmacies, food retail chains, natural products stores, baby product stores, and other parties in the private market.
Additionally, the Rekah Group’s products are purchased and distributed in the Palestinian Authority (the West Bank and Gaza) and in Africa by sub-distributors with which the Group has entered designated agreements.